By - Reuters
- Canada has signed a $56 million contract with a Danish biotechnology company named Bavarian Nordic.
- The deal is for Bavarian Nordic’s smallpox vaccine, which has been approved for use against monkeypox in the country.
- The deliveries are set to start next year.
Danish biotechnology company Bavarian Nordic (CPH: BAVA) said on Tuesday it had signed a $56 million contract with Canada for its smallpox vaccine, which is also approved for use against monkeypox in the country, with deliveries starting next year.
"In parallel, Bavarian Nordic continues to secure contracts with other countries, including Denmark, but also countries outside Europe, to supply the vaccine to mitigate the current monkeypox outbreak", said the firm.
© 2022 Kalkine Media®
Bavarian will also host an investor call later on Tuesday at 1500 CET (1300 GMT).